Correlation between Oncotype DX recurrence score and classical risk factors in early breast cancer.

• DOI: 10.1200/jco.2017.35.15_suppl.e12011
• Publication Date: 2018-09-06T15:39:13Z
• Authors: Fernando Namuche; Rossana Esther Ru...; Claudio J. Flores; Alfredo Aguilar; Henry Leonidas Gomez
• Keywords: Concordance

e12011 Background: OncotypeDx(ODX) predicts the likelihood of estrogen receptor (ER) positive breast cancer (BC) recurrence and assesses likely benefit from both hormonal therapy chemotherapy. Many clinical scores that estimate risk category ODX are being tested. Ki67 is frequently incorporated into these assessments, although there no standard cut-off for its use. Methods: We retrospectively reviewed electronic medical files 190 patients with early stage ER+ BC whom score (RS) was available 2014 to 2016. Our objective find out degree which classical clinicopathological variables -as defined by St. Gallen(SG) 2015- could predict category, also determine an optimal in order establish accurate classification. Chi square test used. Results: Mean age at diagnosis 59 years (28-89). tumor diameter 15mm, 84.2% were intermediate grade. expression ER, PR 87%, 53% 22%, respectively. According 62.1% low risk, 30.5% 7.4% high risk. An overall concordance 46.8% (73/190) found between SG 2015 (75.7% low, 33.3% 23.9% RS). When changing cutoffs ≤20% (for Ki67) ≥30% Ki67), 56.3% (107/190) (69.6% 47.3% RS, p=0.00) (Table 1). Conclusions: In best-case scenario, correctly classified our series. Despite a specialized center, utility predicting limited. [Table: see text]